ArticleClinical and translational allergy2013
Novel birch pollen specific immunotherapy formulation based on contiguous overlapping peptides.
Article in Clinical and translational allergy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01719133 (Détermination de la réactivité cutanée de Volontaires Allergiques au Pollen de Bouleau Contre Des Peptides dérivés de Bet v 1), which is not on this map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Détermination de la réactivité cutanée de Volontaires Allergiques au Pollen de Bouleau Contre Des Peptides dérivés de Bet v 1
Who cites it
23 citing papers in PubMed, 54 citations in OpenAlex.
- Safety and efficacy of immunotherapy with the recombinant B-cell epitope-based grass pollen vaccine BM32.The Journal of allergy and clinical immunology · 2018Trial
- A randomized, double-blind, placebo-controlled, dose-finding trial with Lolium perenne peptide immunotherapy.Allergy · 2018Trial
- Skin test evaluation of a novel peptide carrier-based vaccine, BM32, in grass pollen-allergic patients.The Journal of allergy and clinical immunology · 2015Trial
- Advancement of antigen-specific immunotherapy: knowledge transfer between allergy and autoimmunity.Immunotherapy advances · 2021Review
- Preventive Administration of Non-Allergenic Bet v 1 Peptides Reduces Allergic Sensitization to Major Birch Pollen Allergen, Bet v 1.Frontiers in immunology · 2021Article
- Advances in Food Allergy Treatment.The Yale journal of biology and medicine · 2020Review
- [Recombinant allergens, peptides, and virus-like particles for allergy immunotherapy].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2020Review
- Recombinant allergens for immunotherapy: state of the art.Current opinion in allergy and clinical immunology · 2019Review
- Modified Allergens for Immunotherapy.Current allergy and asthma reports · 2018Review
- Next generation immunotherapy for tree pollen allergies.Human vaccines & immunotherapeutics · 2017Review
- Utility and Comparative Efficacy of Recombinant Allergens Versus Allergen Extract.Current allergy and asthma reports · 2017Review
- [Innovative forms of specific immunotherapy].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2017Review
- Therapeutic vaccines for allergic disease.NPJ vaccines · 2017Article
- Allergen Immunotherapy: Past, Present, and Future.Allergy, asthma & immunology research · 2016Review
- T Cell Epitope Peptide Therapy for Allergic Diseases.Current allergy and asthma reports · 2016Review
- On Peptides and Altered Peptide Ligands: From Origin, Mode of Action and Design to Clinical Application (Immunotherapy).International archives of allergy and immunology · 2016Review
- Immunoregulatory T cell epitope peptides: the new frontier in allergy therapy.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2015Review
- Immunotherapy with B cell epitopes ameliorates inflammatory responses in Balb/c mice.Clinical and experimental immunology · 2015Article
- Modified allergens and their potential to treat allergic disease.Current allergy and asthma reports · 2014Review
- Molecular approach to allergy diagnosis and therapy.Yonsei medical journal · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSynthetic contiguous overlapping peptides (COPs) may represent an alternative to allergen extracts or recombinant allergens for allergen specific immunotherapy. In combination, COPs encompass the entire allergen sequence, providing all potential T cell epitopes, while preventing IgE conformational epitopes of the native allergen.
methodsIndividual COPs were derived from the sequence of Bet v 1, the major allergen of birch pollen, and its known crystal structure, and designed to avoid IgE binding. Three sets of COPs were tested in vitro in competition ELISA and basophil degranulation assays. Their in vivo reactivity was determined by intraperitoneal challenge in rBet v 1 sensitized mice as well as by skin prick tests in volunteers with allergic rhinoconjunctivitis to birch pollen.
resultsThe combination, named AllerT, of three COPs selected for undetectable IgE binding in competition assays and for the absence of basophil activation in vitro was unable to induce anaphylaxis in sensitized mice in contrast to rBet v 1. In addition no positive reactivity to AllerT was observed in skin prick tests in human volunteers allergic to birch pollen. In contrast, a second set of COPs, AllerT4-T5 displayed some residual IgE binding in competition ELISA and a weak subliminal reactivity to skin prick testing.
conclusionsThe hypoallergenicity of contiguous overlapping peptides was confirmed by low, if any, IgE binding activity in vitro, by the absence of basophil activation and the absence of in vivo induction of allergic reactions in mouse and human.
trial registrationClinicalTrials.gov NCT01719133.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.